Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

Ipamorelin dose-dependently increased longitudinal bone growth rate (from 42 to 52 microm/day) and body weight in adult female rats over 15 days of treatment.

Abstract

Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties.. With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c.. three times daily for 15 days to adult female rats.

Key Findings

With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. | Ipamorelin dose-dependently increased LGR from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001).

Study Design

Animal study